{"id":"NCT00398983","sponsor":"M.D. Anderson Cancer Center","briefTitle":"Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)","officialTitle":"Randomized Study of Decitabine Versus Observation or Continued Standard Chemotherapy as Maintenance Therapy for Adults With Unfavorable Risk AML in First Complete Remission (CR) or Adults With Relapsed AML in Second or Greater CR","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2006-08","primaryCompletion":"2012-05","completion":"2012-05","firstPosted":"2006-11-14","resultsPosted":"2013-03-04","lastUpdate":"2013-03-04"},"enrollment":50,"design":{"allocation":"RANDOMIZED","model":"FACTORIAL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acute Myelogenous Leukemia"],"interventions":[{"type":"DRUG","name":"Decitabine","otherNames":["Dacogen"]}],"arms":[{"label":"Decitabine 20 mg/m^2","type":"EXPERIMENTAL"},{"label":"No Study Drug","type":"NO_INTERVENTION"}],"summary":"The goal of this clinical study is to find out whether continued therapy with decitabine after achieving a remission in acute myeloid leukemia (AML) patients can help prolong the remission and prevent relapse of the disease.","primaryOutcome":{"measure":"Number of Participants With Relapse-Free Response at 1 Year","timeFrame":"Baseline to 1 year","effectByArm":[{"arm":"Decitabine 20 mg/m^2","deltaMin":10,"sd":null},{"arm":"No Study Drug","deltaMin":10,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://mdanderson.org"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":20},"commonTop":["Neutropenia","Thrombocytopenia","Infection","Anemia","Fatigue"]}}